Smart drug strategy targets hidden cancer cells in High-Risk CLL
NCT ID NCT05478512
First seen Mar 26, 2026 · Last updated May 26, 2026 · Updated 11 times
Summary
This study tests a two-step treatment plan for young adults (up to age 65) with high-risk chronic lymphocytic leukemia (CLL) who have not had prior therapy. First, patients receive a combination of venetoclax and obinutuzumab. Then, based on whether any cancer cells remain, they either continue venetoclax alone or switch to a stronger combo with zanubrutinib. The goal is to wipe out all traces of the disease and tailor treatment to each person's response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ematologia AO di Perugia
Perugia, Italy
-
Ematologia AOU Careggi
Florence, Italy
-
Ematologia AOUS - Policlinico S. M. alle Scotte
Siena, Italy
-
Ematologia IRST D.Amadori
Meldola, Italy
-
Ematologia Ospedale Infermi
Rimini, Italy
-
Ematologia Ospedale S.M. delle Croci
Ravenna, Italy
-
Ematologia Policlinico Gemelli
Roma, Italy
-
Ematologia Policlinico Umberto I
Roma, Italy
Conditions
Explore the condition pages connected to this study.